Drug Control of Diuretic-Induced Hyperuricemia
| Autor: | Albert N. Brest, Hassan Mehbod, Gaddo Onesti, Charles Heider |
|---|---|
| Rok vydání: | 1966 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Disease Pharmacology Drug control Internal medicine Diabetes mellitus Humans Medicine Hyperuricemia Sulfonamides Probenecid business.industry Sulfonamide (medicine) nutritional and metabolic diseases Quinethazone General Medicine Chlorothiazide medicine.disease Uric Acid Blood Hydrochlorothiazide Endocrinology Hypertension Azotemia Diuretic business medicine.drug |
| Zdroj: | JAMA: The Journal of the American Medical Association. 195:42 |
| ISSN: | 0098-7484 |
| DOI: | 10.1001/jama.1966.03100010098032 |
| Popis: | ORAL SULFONAMIDE diuretics are the mainstays of the current diuretic armamentarium. In addition to the thiazide derivatives, other potent oral sulfonamide diuretics, including phthalimidine and quinazoline drugs, are currently available. The untoward reactions which may be encountered with these various compounds include electrolyte disequilibriums, systemic idiosyncratic reactions, and metabolic alterations. The last-named include azotemia, hyperglycemia, hyperammoniemia, and hyperuricemia. The purpose of this communication is to describe the frequency, significance, and control of hyperuricemia induced by the quinazoline diuretic quinethazone. The reported incidence of hyperuricemia during oral-sulfonamide-diuretic therapy has varied widely, ranging from 1% to 75%. 1,2 This extreme variability probably reflects differences in patient selection, frequency with which serum-uric-acid determinations have been performed, and, possibly, diet. In addition to primary gout, such diverse organic illnesses as coronary-artery disease, diabetes mellitus, and renal disease may affect serum-uricacid levels. Hence the type of patient population will significantly influence the reported findings. Abundant |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|